BTIG Maintains MDxHealth(MDXH.US) With Buy Rating, Cuts Target Price to $6
MDxHealth Is Maintained at Overweight by Piper Sandler
MDxHealth Analyst Ratings
Lake Street Maintains MDxHealth(MDXH.US) With Buy Rating, Maintains Target Price $7
TD Cowen Maintains MDxHealth(MDXH.US) With Buy Rating, Maintains Target Price $7
Piper Sandler Maintains MDxHealth(MDXH.US) With Buy Rating, Cuts Target Price to $6
TD Cowen Maintains MDxHealth(MDXH.US) With Buy Rating, Raises Target Price to $7
MDxHealth Analyst Ratings
Lake Street Initiates MDxHealth(MDXH.US) With Buy Rating, Announces Target Price $7
BTIG Maintains MDxHealth(MDXH.US) With Buy Rating, Maintains Target Price $8
Piper Sandler Maintains MDxHealth(MDXH.US) With Buy Rating, Raises Target Price to $8
MDxHealth (MDXH) Receives a Buy From Piper Sandler
Strong Buy Rating for MDxHealth: Robust Revenue Growth and Strategic Value Proposition
MDxHealth (MDXH) Gets a Buy From BTIG
Analysts Conflicted on These Healthcare Names: MDxHealth (MDXH), OrthoPediatrics (KIDS) and Karuna Therapeutics (KRTX)
Piper Sandler Sticks to Its Buy Rating for MDxHealth (MDXH)
MDxHealth Analyst Ratings
Buy Rating Affirmed for MDxHealth Amid Strong Q4 Performance and Positive Future Outlook
Piper Sandler Sticks to Their Buy Rating for MDxHealth S.A. Sponsored ADR (MDXH)
MDxHealth S.A. Sponsored ADR (MDXH) Gets a Buy From BTIG
No Data
No Data